Drug therapy for ocular allergy

Bibliography

• FRIEDLANDER MH: Conjunctivitis of allergic origin: clinical presentation and differential diagnosis. Surv. Ophthalmol. (1993) 38 (Suppl):105–114.
   Google Scholar
• BUCKLEY RJ: Vernal keratoconjunctivitis. Int. Ophthal-mol. Din. (1989) 28:303–308.
   Web of Science ®Google Scholar
• FOSTER CS, CALONGE M: Atopic keratoconjunctivitis. Ophthalmology (1990) 97:992–1000.
   PubMed Web of Science ®Google Scholar
• GREINER JV, FOWLER SA, ALLANSMITH MR: Giant papil-lary conjunctivitis. In: The CLAO Guide to Basic Science and Clinical Practice. Dabezies O, Cavanagh HD (Eds.). Grune & Stratton, New York (1986) 43.1-43.11.
   Google Scholar
• FRIEDLANDER MH: Contact allergy and toxicity in the eye. Int. Ophthalmol. (1988) 28:317–319.
   Web of Science ®Google Scholar
• HINGORANI M, LIGHTMAN S: The immunopathogene-sis of atopic eye disease. CML Allergy (1997) 5:31–40.
   Google Scholar
• HOLGATE ST: The mast cell and its functions in allergic disease. Din. Exp. Allergy (1991) 21 (Suppl. 3):11–16.
   Google Scholar
• SERAFIN WE, AUSTEN KF: Mediators of immediate hy-persensitivity reactions. New Eng. J. Med. (1987) 317:30–34.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ LB: Preformed mediators of human mast cells and basophils. In: Mast Cells, Mediators and Disease. Holgate ST (Ed.), Kluwer Academic Publishers, Lancaster (1988):129–148.
   Google Scholar
• ABELSON MB, UDELL IJ: 112-receptors in the human ocu-lar surface. Arch. Ophthalmol. (1981) 99:302–304.
   PubMed Web of Science ®Google Scholar
• LEON J, CHARAP A, DUZMAN E, SHEN C: Efficacy of ci-metidine/pyrilamine eye drops, a dose response study with histamine challenge. Ophthalmology (1986) 93:120–123.
   PubMed Web of Science ®Google Scholar
• BUTRUS SI, ABELSON MB: Laboratory evaluation of ocu-lar allergy. Int. Ophthalmol. Din. (1988) 28:324–328.
   PubMedGoogle Scholar
• BUTRUS SI, OCHSNER KI, ABELSON MB et al.: The level of tryptase in human tears. An indicator of activation of conjunctival mast cells. Ophthalmology (1990) 97:1678–1683.
   Google Scholar
• TAM EK, CAUGHEY GH: Degradation of airway neuro-peptides by human lung tryptase. Am. I. Respir. Cell Mol. Biol. (1990) 3:27–32.
   PubMed Web of Science ®Google Scholar
• WALLS AF, HE S, TERAN LM et al.: Granulocyte recruit-ment by human mast cell tryptase. Int. Arch. Allergy Im-munol. (1995) 107:372–373.
   PubMed Web of Science ®Google Scholar
• ROBINSON C: Mast cells and newly-generated lipid me-diators. In: Mast Cells, Mediators and Disease. Holgate ST (Ed.), Kluwer Academic Publishers, Lancaster (1988):149–174.
   Google Scholar
• ABELSON MB, BUTRUS SI, KLIMAN GH et al.: Topical ara-chidonic acid: a model for screening antiinflamma-tory agents. J. Ocul. Pharmacol. (1987) 3:63–75.
   PubMedGoogle Scholar
• ABELSON MB, MADIWALE NA, WESTON JH: The role of prostaglandin D2 in allergic ocular diseases. In: Ad-vances in Immunology and Immunopathology of the Eye. O'Connor GR, Chandler JW (Eds.), Masson, New York (1985):163–168.
   Google Scholar
• SPADA CS, WOODWARD DF, HAWLEY SB, NIEVES AL:Leukotrienes cause eosinophil emigration into con-junctival tissue. Prostaglandins (1986) 31:795–809.
   PubMedGoogle Scholar
• TROCME SD, GILBERT CM, ALLANSMITH MR et al.: Char-acteristics of the cellular response of the rat conjunc-tiva to topically applied leukotriene Bg. Ophthalmic Res. (1989) 21:297–302.
   PubMed Web of Science ®Google Scholar
• BISGAARD H, FORD-HUTCHINSON AW, CHARLESON S,TAUDERF E: Production of leukotrienes in human skin and conjunctival mucosa after specific allergen chal-lenge. Allergy (1985) 40:417–423.
   PubMed Web of Science ®Google Scholar
• DHIR SP, GANG SK, SHARMA YR, LATH MC: Prosta-glandins in human tears. Am. J. Ophthalmol, (1979) 87:403–404.
   PubMed Web of Science ®Google Scholar
• ABELSON MB: Lipoxygenase products in ocular inflam-mation. Invest. Ophthalmol, Vis, Sci, (1983) 24(Suppl):42.
   Google Scholar
• KROEGEL C, VIRCHOW JC, KORTSIK J, MATTHYS H: Cyto-kines, platelet activating factor and eosinophils in asthma. Resp, Med. (1992) 86:375–389.
   PubMed Web of Science ®Google Scholar
• WARDLAW AJ, MOQBEL R, CROMWELL O, KAY AB: Plate-let activating factor: a potent chemotactic and che-mokinetic factor for human eosinophils. J. Din. Invest. (1986) 78:1701–1706.
   PubMed Web of Science ®Google Scholar
• THAKUR A, WILLCOX MDP, MORRIS C, HOLDER BA: In-flammatory mediators of tear fluid and their role in corneal inflammation. Invest. Ophthalmol, Vis, Sci. (1996) 37 (Suppl.):S234.
   Google Scholar
• BRAQUET P, VIDAL RF, BRAQUET M et al.: Involvementof leukotrienes and PAF-acether in the increased microvascular permeability of the rabbit retina. Agents Actions (1984) 15:82–85.
   Google Scholar
• STOCK EL, ROTH SI, KIM ED, WALSH MK, THAMMAN R:The effect of platelet-activating factor (PAF), histamine and ethanol on vascular permeability of the guinea pig conjunctiva. Invest. Ophthalmol, Vis, Sci, (1990) 31:987–992.
   PubMed Web of Science ®Google Scholar
• GEORGE MA, SMITH LM, BERDY GJ et al.: Platelet activat-ing factor induced inflammation following topical ocular challenge. Invest. Ophthalmol, Vis, Sci, (1990) 31 (Suppl.):63.
   Google Scholar
• MONDINO BJ, PHINNEY R: The complement system in ocular allergy. Int. Ophthalmol, Din. (1988) 28:329–331.
   PubMedGoogle Scholar
• BALLOW M, DONSHIK PC, MENDELSON L: Complement proteins and C3 anaphylotoxin in the tears of patients with conjunctivitis. J. Allergy Clin. lmmunol. (1985) 76:473–476.
   Google Scholar
• PROUD D, SWEET J, STEIN P et al.: Inflammatory media-tor release on conjunctival provocation of allergic sub-jects with allergen. J. Allergy Din. Immunol, (1990) 85:896–905.
   PubMed Web of Science ®Google Scholar
• FOREMAN JC: Neuropeptides and the pathogenesis ofallergy. Allergy (1987) 42:1–11.
   PubMed Web of Science ®Google Scholar
• SMITH CH, BARKER JN, LEE TH: Adhesion molecules inallergic inflammation. Am. Rev. Respir, Dis, (1993) 148:S75–8
   PubMedGoogle Scholar
• BACON AS, BADDELEY S, MCGILL JI, HOLGATE ST,LIGHTMAN SL: Upregulation of adhesion molecules in allergic eye disease and relationship to leukocyte infil-tration. Invest. Ophthalmol, Vis, Sci, (1998). Submitted.
   Google Scholar
• SAIGA T, WIN T, SHIMIZU Y, ISHIZAKI M, LEONARDI A:Immunohistochemical study of the adhesion mole-cules in the conjunctiva of vernal keratoconjunctivitis. XVth International Congress ofAllergology & Clinical Immu-nology. Stockholm, Sweden (1994):14.
   Google Scholar
• TABBARA KF, EL-ASRAR AM, GEBOES K et al.: Adhesion molecules in vernal keratoconjunctivitis. Invest. Oph-thalmol, Vis, Sci, (1996) 37(Suppl.):51022.
   Google Scholar
• RESNICK MB, WELLER PF: Mechanisms of eosinophil re-cruitment. Am. J. Respir, Cell Mol, Biol. (1993) 8:349–55
   PubMed Web of Science ®Google Scholar
• CIPRANDI G, BUSCAGLIA S, PESCE G et al.: Allergic sub-jects express ICAM-1 on epithelial cells of conjunctiva after allergen challenge. J. Allergy Din. Immunol, (1993) 91:783–792.
   PubMed Web of Science ®Google Scholar
• CIPRANDI G, BUSCAGLIA S, PESCE GP, CANONICA GW:ICAM-1/CD54 expression on conjunctival epithelium during pollen season. Allergy (1995) 50:184–187.
   PubMed Web of Science ®Google Scholar
• HINGORANI M, CALDER V, BUCKLEY R, LIGHTMAN S:Upregulation of ICAM-1 expression on conjunctival epithelial cells in ocular allergic diseases. Fourth Inter-national Symposium on Ocular Inflammation. London, UK (1996).
   Google Scholar
• GILL KS, YANNARIELLO-BROWN J, PATEL J et al.: ICAM-1expression in corneal epithelium of a patient with ver-nal keratoconjunctivitis: case report. Cornea (1997) 16:107–111.
   PubMed Web of Science ®Google Scholar
• IRANI AM, BUTRUS SI, TABBARA KF, SCHWARTZ LB: Hu-man conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary con-junctivitis. J. Allergy Din. Immunol, (1990) 86:34–40.
   PubMed Web of Science ®Google Scholar
• BADDELEY SM, BACON AS, MCGILL JI et al.: Mast cell dis-tribution and neutral protease expression in acute and chronic allergic conjunctivitis. Din. Exp. Allergy (1995) 25:41–50.
   PubMed Web of Science ®Google Scholar
• MACLEOD JDA, ANDERSON DF, BADDELEY SM et al.: Im-munolocalisation of cytokines to human mast cells in conjunctiva from normal seasonal allergic and aller-gen challenged subjects. Vis, Res. (1995) 35:S175.
   Google Scholar
• MACLEOD JDA, ANDERSON DF, BADDELEY SM et at.: Mast cell cytokines in seasonal allergic conjunctivitis. Invest. Ophthalmol, Vis, Sci, (1996) 37 (Suppl.):S235.
   Google Scholar
• ANDERSON DF: The conjunctival late-phase reaction and allergen provocation in the eye. Din. Exp. Allergy (1996) 26:1105–1107.
   PubMed Web of Science ®Google Scholar
• METZ DP, BACON AS, HOLGATE S, LIGHTMAN SL: Pheno-typic characterisation of T-cells infiltrating the con-junctiva in chronic allergic eye disease. J. Allergy Din. Immunol, (1996) 98:686–696.
   PubMed Web of Science ®Google Scholar
• HENRIQUEZ AS, KENYON KR, ALLANSMITH MR: Mast cellultrastructure. Comparison in contact lens-associated giant papillary conjunctivitis and vernal conjunctivi-tis. Arch. Ophthalmol, (1981) 99:1266–1272.
   Google Scholar
• FOSTER CS, RICE BA, DUTT JE: Immunopathology ofatopic conjunctivitis. Ophthalmology (1991) 98:1190–1196.
   PubMed Web of Science ®Google Scholar
• BONINI S, BONINI S, LAMBIASE A et al.: Vernal kerato-conjunctivitis: a model of 5q cytokine gene cluster dis-ease. Int. Arch. Allergy Immunol, (1995) 107:95–98.
   PubMed Web of Science ®Google Scholar
• OHSHIMA Y, KATAMURA K, MIURA M, MIKAWA H, MA-YUMI M: Serum levels of interleukin 4 and soluble CD23 in children with allergic disorders. Eur, J. Ped, (1995) 54:723–728.
   Google Scholar
• FUJISHIMA H, TASKEUCHI T, SHINOZAKI N, SAITO I,TSUBOTA K: Measurement of IL-4 in tears of patients with seasonal allergic conjunctivitis and vernal kera-toconjunctivitis. Din. Exp. Immunol, (1995) 102:395–398.
   PubMed Web of Science ®Google Scholar
• ROMAGNANI S, MAGGI E, PARRONCHI P et al.: Increasednumbers of Th2-like CD4+ T cells in target organs and in the allergen-specific repertoire of allergic patients. Possible role of IL-4 produced by non-T-cells. Int. Arch. Allergy Appl, Immunol, (1991) 94:133–136.
   Web of Science ®Google Scholar
• MAGGI E, BIS WAS P, DELPRETE G et al.: Accumulation ofTh-2 like helper T cells in the conjunctiva of patients with vernal conjunctivitis. J. Immunol, (1991) 146:1169–1174.
   PubMed Web of Science ®Google Scholar
• METZ DM, BONINI S, LIGHTMAN S: mRNA expressionfor interleukin 2 and interleuki-n5 in vernal kerato-conjunctivitis. Inv. Ophthalmol, Vis, Sci, (1993) 34: (Suppl.):857.
   Google Scholar
• METZ DP, HINGORANI M, CALDER VL, BUCKLEY RJ, LIGHTMAN SL: T-cell cytokines in chronic allergic eye disease. J. Allergy Din. Immunol, (1998). (In Press.)
   Google Scholar
• MAGGI E, ROMAGNANI S: Role of T-cells and T-cell-derived cytokines in the pathogenesis of allergic dis-eases. IVY Acad. Sci, (1994) 725:2–12.
   PubMed Web of Science ®Google Scholar
• ABELSON MB, SCHAEFER K: Conjunctivitis of allergicorigin: immunologic mechanisms and current ap-proaches to therapy. Surv. Ophthalmol, (1993) 38: (Suppl.) :115–132.
   Google Scholar
• HINGORANI M, CALDER V, JOLLY G, BUCKLEY RJ, LIGHT-MAN SL: Eosinophil surface antigen expression and cy-tokine production varies in different ocular allergic diseases. J. Allergy Din. Immunol, (1998). Submitted.
   Google Scholar
• TROCME SD, KEPHART GM, ALLANSMITH MR, BOURNEWM, GLEICH GJ: Conjunctival deposition of eosinophil granule major basic protein in vernal keratoconjuncti-vitis and contact lens associated giant papillary con-junctivitis. Am. J. Ophthalmol, (1989) 108:57–63.
   PubMed Web of Science ®Google Scholar
• PORTER DP, TROCME SD, FOSTER CS et al.: Conjunctivaldeposition of eosinophil major basic protein, neutro-phil elastase and mast cell tryptase in atopic kerato-conjunctivitis. Inv. Ophthalmol, Vis, Sci, (1993) 34 (Suppl.):855.
   Google Scholar
• TROCME SD, KEPHART GM, BOURNE WM, BUCKLEY RJ, GLEICH GJ: Eosinophil major basic protein deposition in corneal ulcers associated with vernal keratocon-junctivitis. Am. J. Ophthalmol, (1993) 115:640–643.
   PubMed Web of Science ®Google Scholar
• TROCME SD, GLEICH GJ, KEPHART GM, ZEISKE JD: Eosi-nophil granule major basic protein inhibition of cor-neal epithelial wound healing. Invest. Ophthalmol, Vis, Sci, (1994) 35:3051–3056.
   PubMed Web of Science ®Google Scholar
• HINGORANI M, CALDER V, BUCKLEY RJ, LIGHTMAN SL: Eosinophil production of IL-8 in chronic allergic eye disease. Invest. Ophthalmol, Vis, Sci, (1996) 37(Suppl.):S1021.
   Google Scholar
• HINGORANI M, LIGHTMAN S: Therapeutic options in ocular allergic disease. Drugs (1995) 50:208–221.
   PubMed Web of Science ®Google Scholar
• JAANUS SD: Anti-inflammatory drugs. In: Clinical Ocu-lar Pharmacology (Edition 2). Bartlett JD, Jaanus SD (Eds.),Butterworth, Toronto (1989) Chapter 5.
   Google Scholar
• SMITH JP, LANIER BQ, TREMBLEY N, WARD RL, DEFALLER JM: Treatment of allergic conjunctivitis with ocular de-congestants. Cum Eye Res. (1982) 32:141–147.
   Google Scholar
• ABELSON MB, PARADIS A, GEORGE MA et al.: Effects ofVasocon-A in the allergen challenge model of acute al-lergic conjunctivitis. Arch. Ophthalmol, (1990) 108:520–524.
   PubMed Web of Science ®Google Scholar
• FRIEDLANDER MH: Current concepts in ocular allergy. Ann. Allergy (1991) 67:5–10.
   PubMedGoogle Scholar
• ABELSON MB, BUTRUS SI, WESTON JH, ROSNER B: Toler-ance and absence of rebound vasodilatation following topical ocular decongestant usage. Ophthalmology (1984) 91:1364–1367.
   PubMed Web of Science ®Google Scholar
• DECHANT KL, GOA KL: Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and con-junctivitis. Drugs (1991) 41:202–224.
   Google Scholar
• PARYS W, BLOCKHUYS S, JANSSENS M et al.: New trends in the treatment of allergic conjunctivitis. Doc. Oph-thalmol, (1992) 82:353–360.
   PubMed Web of Science ®Google Scholar
• AZEVEDO M, CASTEL-BRANCO MG, OLIVEIRA JF et al.: Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treat-ment of seasonal allergic conjunctivitis. Cl/n. Exp. Al-lergy (1991) 21:689–694.
   PubMed Web of Science ®Google Scholar
• BENDE M, PIPKORN U: Topical levocabastine, a selec-tive Hi antagonist in seasonal allergic rhinoconjuncti-vitis. Allergy (1987) 42:512–515.
   PubMed Web of Science ®Google Scholar
• DAVIES BH, MULLINS J: Topical levocabastine is more effective than sodium cromoglycate for the prophy-laxis and treatment of seasonal allergic conjunctivitis. Allergy (1993) 48:519–524.
   PubMed Web of Science ®Google Scholar
• PIPKORN U, BENDE M, HENDER J, HENDER T: A double blind evaluation of topical levocabastine; a new spe-cific Hi antagonist in patients with allergic conjuncti-vitis. Allergy (1985) 40:491–496.
   PubMed Web of Science ®Google Scholar
• CIPRANDI G, CENQUETI PM, SACCA S et al: Levoca-bastine versus cromolyn sodium in the treatment of pollen-induced conjunctivitis. Ann. Allergy (1990) 65:156–158.
   PubMedGoogle Scholar
• FROSTAAD AB, OLSEN AK: A comparison of topical levocabastine and sodium cromoglycate in the treat-ments of pollen-provoked seasonal allergic conjuncti-vitis. Din. Exp. Allergy (1993) 23:406–409.
   PubMed Web of Science ®Google Scholar
• JANSSENS M, BLOCKHUYS S: Tolerability of levoca-bastine eye drops. Doc. Ophthalmol, (1993) 84:111–118.
   PubMed Web of Science ®Google Scholar
• JANSSENS MML, VANDEN BUSSE G: Levocabastine: an ef-fective topical treatment for allergic rhinoconjunctivi-tis. Din. Exp. Allergy (1991) 21 (Suppl. 2):29–36.
   Google Scholar
• ODELRAM H, BJORKSTEIN B, AFKLERCHER T et al.: Topi-cal levocabastine versus sodium cromoglycate in al-lergic conjunctivitis. Allergy (1989) 44:432–436.
   PubMed Web of Science ®Google Scholar
• TISZLER CIESLIK E, NOWAK W, GLUZA J: A comparisonof levocabastine and sodium cromoglycate with aller-gic conjunctivitis due to house dust mite. XVth Interna-tional Congress of Allergology and Clinical Immunology Stockholm, Sweden. Hoegrefe & Huber, Seattle (199016.
   Google Scholar
• CIPRANDI G, BUSCAGLIA S, CERQUETI PM, CANONICAGW: Drug treatment of allergic conjunctivitis: a review of the evidence. Drugs (1992) 43:154–176.
   PubMed Web of Science ®Google Scholar
• HOWARTH PH, EMANUEL MB, HOLGATE ST: Astemizole,a potent histamine Hi receptor antagonist: effect in al-lergic rhinoconjunctivitis on antigen and histamine induced skin wheal response and relationship to se-rum levels. Br. J. Pharmacol, (1984)18:1–8.
   Web of Science ®Google Scholar
• CIPRANDI G, BUSCAGLIA S, MARCHESI E et al.: Protectiveeffect of loratidine on late phase reaction induced by conjunctival provocation test. Int. Arch. Allergy Immu-nol, (1993) 100:185–189.
   PubMed Web of Science ®Google Scholar
• BUSSCHE GV, EMANUEL MB, ROMBAUT N: Clinical pro-file of astemizole. A survey of 50 double-blind trials. Ann. Allergy (1987) 58:184–188.
   Google Scholar
• SCHOENEICH M, PECOUD AR: Effect of cetirizine in aconjunctival provocation test with allergens. Din. Exp. Allergy (1990) 20:171–174.
   PubMed Web of Science ®Google Scholar
• WOOSLEY R: Cardiac actions of antihistamines. Ann.Rev. Pharmacol, Toxicol, (1996) 36:233–252.
   PubMed Web of Science ®Google Scholar
• COX JSG: Disodium cromoglycate: mode of action andits possible relevance to the clinical use of the drug. Br. J. Dis, Chest (1971) 65:189–204.
   PubMedGoogle Scholar
• SPATARO AC, BOSMAN HB: Mechanism of action of di-sodium cromoglycate - mast cell calcium ion reflux af-ter a histamine-releasing stimulus. Biochem, Pharmacol, (1976) 25:505–510.
   PubMed Web of Science ®Google Scholar
• BRUIJINZEL PLB, WARRINGA RAJ, KOH PTM, KREUHMETJ: Inhibition of neutrophil and eosinophil induced chemotaxis by nedocromil sodium and sodium cro-moglycate. Br. J. Pharmacol, (1990) 99:798–802.
   PubMed Web of Science ®Google Scholar
• KAY AB, WALSH GM, MOQBEL R et al.: Disodium cromo-glycate inhibits activation of human inflammatory cells in vitro. J. Allergy Din. Immunol, (1987) 80:1–8.
   PubMed Web of Science ®Google Scholar
• DAHLEN SE, BJORCK T, KUMLI M et al.: Dual inhibitory action of nedocromil sodium on antigen induced in-flammation. Drugs (1989) 37 (Supp1.1):63–68.
   Google Scholar
• JOSEPH M, TSICOPOULOS A, TONNEL AB, CAPRON A: Modulation by nedocromil sodium of immunologic and nonimmunologic activation of monocytes, macrophages and platelets. J. Allergy Din. Immunol, (1993) 92:165–170.
   PubMed Web of Science ®Google Scholar
• ALLANSMITH MR, ROSS RN: Ocular allergy and mast cell stabilisers. Sun/. Ophthalmol, (1986) 30:229–244.
   PubMed Web of Science ®Google Scholar
• COLLUM LMT, FITZSIMON S, HILLERY M et al.: Twice daily 4% sodium cromoglycate vs 2% sodium used four times daily in seasonal (grass pollen) allergic conjunc-tivitis. Doc. Ophthalmol, (1992) 82:267–277.
   PubMed Web of Science ®Google Scholar
• EL HENNAWI M: A comparison between 2% and 4% so-dium cromoglycate eye drops in the treatment of ver-nal keratoconjunctivitis. Cum Eye Res. (1983) 2:765–768.
   Web of Science ®Google Scholar
• LINDSAY-MILLER ACM: Group comparative trial of 2% sodium cromoglycate (Opticrom) with placebo in the treatment of seasonal allergic conjunctivitis. Din. Al-lergy (1979) 9:271–275.
   Web of Science ®Google Scholar
• KNOTTNERUS IG, SCOTT CN, RILEY PA: Nedocromil so-dium 2% ophthalmic solution (TILAVIST). A new topi-cal treatment for ocular allergic inflammation. Ocular Immunol, Inflamm, (1993) 1:27–30.
   Google Scholar
• ALEXANDER M: Comparative therapeutic studies with Tilavist. Allergy (1995) 50\(Suppl. 21):23–29.
   Google Scholar
• KJELLMAN NIM, STEVENS MT: Clinical experience with Tilavist: an overview of efficacy and safety. Allergy (1995) 50\(Suppl. 20:14–22.
   Google Scholar
• WEINS JJ, JACKSON WB: New directions in therapy for ocular allergy. Int. Ophthalm, Din. (1988) 28:332–337.
   PubMed Web of Science ®Google Scholar
• FAHY G, EASTY DL, COLLUM L: Randomised double-masked trial of lodoxamide and sodium cromoglycate in allergic eye disease. A multicentre study. Eur, J. Oph-thalmol, (1992) 2:144–149.
   Google Scholar
• SANTOS CI, HUANG AJ, ABELSON MB et al.: Efficacy of lo-doxamide 0.1% ophthalmic solution in resolving cor-neal epitheliopathy associated with vernal keratoconjunctivitis. Am. J. Ophthalmol, (1994) 117:488–497.
   Google Scholar
• CALDWELL DR, VERIN P, HARTWICH-YOUNG R et al.: Effi-cacy and safety of lodoxamide 0.1% versus cromolyn sodium 4% in patients with vernal keratoconjunctivi-tis. Am. J. Ophthalmol. (1992) 113:632–637.
   Google Scholar
• Lodoxamide for vernal keratoconjunctivitis [Edito-rial]. Med. Letter Drug Then (1994) 36:26.
   PubMedGoogle Scholar
• FRIEDLANDER MH: Management of ocular allergy. Ann. Allergy Asthma Immunol, (1995) 75:212–222.
   PubMed Web of Science ®Google Scholar
• STOCK EL, PENDLETON RB: Pharmacological treatment of ocular allergic diseases. Int. Ophthalmol, Din. (1993) 33:47–58.
   PubMedGoogle Scholar
• BOREL JF, BAUMANN G, CHAPMAN I et al.: In vivo phar-macological effects of ciclosporin and some ana-logues. Adv. Pharmacol, (1996) 35:115–246.
   PubMedGoogle Scholar
• BLEIK JH, TABBARA KF: Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology (1991) 98:1679–1684.
   PubMed Web of Science ®Google Scholar
• HOLLAND EJ, OLSEN TW, KETCHAM JM et al.: Topical ci-closporin A in the treatment of anterior segment in-flammatory diseases. Cornea (1993) 12:413–419.
   PubMed Web of Science ®Google Scholar
• HINGORANI M, MOODALEY L, CALDER V, BUCKLEY RJ, LIGHTMAN S: The use of topical cyclosporin A to re-place topical steroids in atopic keratoconjunctivitis. Annual Congress of the Royal College of Ophthalmologists. Royal College of Ophthalmologists, London, UK (1997).
   Google Scholar
• BENEZRA D, PE'ER J, BRODSKY M, COHEN E: Cyclospor-ine eye drops for the treatment of severe vernal kera-toconjunctivitis. Am. J. Ophthalmol, (1986) 101:278–282.
   PubMed Web of Science ®Google Scholar
• SECCHI AG, TOGNON MS, LEONARDI A: Topical use of cyclosporine in the treatment of vernal keratocon-junctivitis. Am. J. Ophthalmol, (1990) 110:641–645.
   PubMed Web of Science ®Google Scholar
• SECCHI AG, TOGNON MS, LEONARDI A: Topical cyclosporine-A in the treatment of vernal and other immunologically mediated keratoconjunctivitis. In: Ocular Immunology Today. Usui M, Ohno S, Aoki K (Eds.), Elsevier Science Publishers, Amsterdam (1990):37–42.
   Google Scholar
• HOANG-XUAN T, PRISANT O, HANNOUCHE D, ROBIN H: Systemic cyclosporine A in severe atopic keratocon-junctivitis. Ophthalmology (1997) 104:1300–1305.
   PubMed Web of Science ®Google Scholar
• FLEISCH JH, RINKEMA LE, HAISCH KD, WHITESITT CA: Pharmacologic analysis of LY188695 (KB-2413), 142-ethoxyethyl) -2- (4-methy1-1-homopiperazinyl) -be-nzimidazole difumarate, a potent histamine-1 recep-tor antagonist. Agents Actions (1987) 20:40–49.
   PubMedGoogle Scholar
• SHARIF NA, YANNI JM: Emedastine: a potent, high affin-ity histamine Hi-receptor-selective antagonist for ocu-lar use: receptor binding and second messenger studies. J. Ocular Pharmacol, (1994) 10:653–663.
   PubMedGoogle Scholar
• OKUDA M: Effects of emedastine on Japanese cedar pollenosis. A multicentred, double-blind study. Pract, °tot. Kyoto (1995) 88:797–816.
   Google Scholar
• YAMAGIWA M, FUJITA K: Emedastine difumarate in treatment of perennial nasal allergy: an acoustic study. Pract, °tot. Kyoto (1995) 88:263–269.
   Google Scholar
• YANNI JM, STEPHENS DJ, PARNELL DW, SPELLMAN JM: Preclinical efficacy of emedastine, a potent, selective histamine Hi antagonist for topical ocular use. I Ocu-lar Pharmacol. (1994) 10:665–675.
   PubMedGoogle Scholar
• LOWRY GM, ABELSON M, RUBIN JM: Emedastine oph-thalmic solution alleviates ocular itching and redness associated with allergic conjunctivitis. Invest. Ophthal-mot. Vis, Sci, (1996) 37 (Suppl.):S593.
   Google Scholar
• HAMASAKI Y, SHAFIGEH M, YAMAMOTO S et al.: Inhibi-tion of leukotriene synthesis by azelastine. Ann. Allergy Asthma Immunol, (1996) 376:469–475.
   Google Scholar
• LAFORCE C, DOCKHORN RJ, PRENNER BM et al.: Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multi-center trial. Ann. Allergy Asthma Immunol, (1996) 76:181–188.
   PubMed Web of Science ®Google Scholar
• DAVIES RJ, BAGNALL AC, MCCABE RN, CALDERON MA, WANG JH: Antihistamines: topical vs. oral administra-tion. Din. Exp. Allergy (1996) 26 (Suppl. 3):11–17.
   Google Scholar
• AZELASTINE-ASTHMA STUDY GROUP. An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. J. Allergy Din. Immunol, (1996) 97:1218–1224.
   PubMed Web of Science ®Google Scholar
• HORAK F, BERGER U, MENAPACE R, SHUSTER N: Quanti-fication of conjunctival vascular reaction by digital im-aging. J. Allergy Din. Immunol, (1996) 98:495–500.
   PubMed Web of Science ®Google Scholar
• BERDY GJ, ABELSON MB, GEORGE MA, SMITH LM, GIOVANONI RL: Allergic conjunctivitis: a survey of new antihistamines. I Ocular Pharmacol, (1991) 7:313–324.
   PubMedGoogle Scholar
• SUGAR J, NYBERG M, BERNSTEIN J et al.: Imipramine in-hibition of ragweed allergic conjunctivitis. Invest. Oph-thalmol, Vis, Sci, (1984) 25:217–218.
   PubMed Web of Science ®Google Scholar
• SHARIF NA, XU SX, YANNI JM: Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting Hi-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J. Ocular Pharmacol, (1996) 12:401–407.
   Google Scholar
• YANNI JM, STEPHENS DJ, MILLER ST et al.: The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J. Ocular Pharmacol, (1996) 12:389–399.
   Google Scholar
• SPITALNY L, ABELSON M: Olopatadine ophthalmic solu-tion decreases itching and redness associated with al-lergic conjunctivitis. Invest. Ophthalmol, Vis, Sci, (1996) 37:S593.
   Google Scholar
• WRIGHT CD, DEVALL LJ, AKER DO, THUESON DO, CON-ROY MC: Differential regulation of the activation of hu-man eosinophils, macrophages and neutrophils: effect of the allergic mediator release inhibitor CI-959. Agents Actions (1990) 31:11–15.
   PubMedGoogle Scholar
• CONNOR DT, CETENKO WA, MULLICAN MD et al.: Novel benzothiophene-, benzofuran-, and naphthalenecar-boxamidotetrazoles as potential antiallergy agents. J. Med. Chem. (1992) 35:958–965.
   PubMed Web of Science ®Google Scholar
• DONG MK, WILBURN DJ, CONROY MC, GILBERTSEN RB: Inhibition of interleukin-2 production and lympho-cyte responsiveness by the cell activation inhibitor, CI-959. Agents Actions (1991) 34:53–55.
   PubMedGoogle Scholar
• GILBERTSEN RB, DONG MK, WILBURN DJ, CULLINEN KM, CONROY MC: Effects on cytokine release and leukocyte responsiveness. FASEB J (1990) 4:A1770.
   Google Scholar
• FERIN MA, CONROY MC, WRIGHT CD: Inhibition of neu-trophil adhesion to lipopolysaccharide-stimulated hu-man umbilical vein endothelial cells by CI-959. FASEB J. (1992) 6:A1891.
   Google Scholar
• FERIN MA, CONROY MC, WRIGHT CD: Inhibition of neu-trophil adhesion to TNF-stimulated human umbilical vein endothelial cells by CI-959. FASEBJ (1991) 5:A526.
   Google Scholar
• UNANGST PC, CONNOR CT, LOW JE, CONROY MC: CI-959. Drugs Future (1994) 19:117–122.
   Google Scholar
• BENNICH H, RAGNARSSON U, JOHANSSON SGO et al.: Failure of the putative IGE pentapeptide to compete with IgE for receptors on basophils and mast cells. Int, Arch, Allergy Appl. Immunol, (1977) 53:459–468.
   PubMedGoogle Scholar
• EL-DEFRAWY S, JACKSON W: New directions in therapy for ocular allergy. Int. Ophthalmol, Cl/n. (1996) 36:25–44.
   PubMed Web of Science ®Google Scholar
• PRENNER BM: Double-blind placebo-controlled trial of intranasal IgE pentapeptide. Ann, Allergy (1987) 58:332–335.
   PubMedGoogle Scholar
• ABELSON MB, SMITH LM, GEORGE MA et al.: The efficacy of a new anti-allergic agent, Pentyde, in the allergen challenge model of allergic conjunctivitis. Invest, Oph-thalmol, Vis, Sc!. (1991) 32 (Suppl.):86.
   Google Scholar
• FLOYD R, KALPAXIS J, THAYER T et al.: Double-blind comparison of HEPP (IgE pentapeptide) 0.5% ophthal-mic solution and sodium cromoglycate ophthalmic so-lution 4% in patients having atopic conjunctivitis. Invest, Ophthalmol,Sc.', (1988) 29(Suppl.):45.
   Google Scholar
• KAWASHIMA T, IWAMOTO I, NAKAGAWA N, TOMIOKA H, YOSHIDA S: Inhibitory effect of pemirolast, a novel antiallergic drug, on leukotriene C4 and granule pro-tein release from human eosinophils. Int, Arch, Allergy ImmunoL (1994) 103:405–409.
   PubMed Web of Science ®Google Scholar
• KEMP JP, BERNSTEIN IL, BIERMAN CW et al.: Pemirolast, a new oral nonbronchodilator drug for chronic asthma. Ann, Allergy (1992) 68:488–491.
   PubMedGoogle Scholar
• TINKELMAN DG, BERKOWITZ RB: A pilot study of pemi-rolast in patients with seasonal allergic rhinitis. Ann Allergy (1991) 66:162–165.
   PubMedGoogle Scholar
• HAYASHI M, KUROSE T, DOURA Y, HIKIDA M: Effect of topical treatment with pemirolast potassium on ex-perimental allergic conjunctivitis in guinea pigs. In-vest, Ophthalmol, Vis, Sc!. (1992) 33 (Suppl.):1112.
   Google Scholar
• WILHELMS OH: Inhibition profiles of picumast and ke-totifen on the in vitro release of prostanoids, slow re-acting substance of anaphylaxis, histamine and enzyme from human leukocytes and rat alveolar macrophages. Int. Arch, Allergy Appl, ImmunoL (1987) 82:547–549.
   PubMedGoogle Scholar
• FRANKE W, MESSINGER D: Double-blind multicenter controlled clinical study comparing the efficacy of picumast dihydrochloride versus astemizole and pla-cebo in patients with seasonal allergic rhinitis. Drug Res, (1989) 39:1360–1362.
   Web of Science ®Google Scholar
• BOERNER D, METZ K, EBERHARDT R: Efficacy and toler-ability of picumast dihydrochloride in comparison with placebo in asthmatic patients. Drug Res, (1989) 39:1363–1367.
   Web of Science ®Google Scholar
• MOQBEL R, HARTNELL A, KAY AB: The effects of picu-mast on human eosinophil and neutrophil activation. Cl/n. Exp. Allergy (1991) 21:39–44.
   PubMed Web of Science ®Google Scholar
• ROSCH A, SCHAUMANN W, WILHELMS OH: Picumast and mast cell function. Cl/n. Exp. Allergy (1991) 21:17–22.
   PubMed Web of Science ®Google Scholar
• BENT S, GREVEN T, BRAAM U et al.: Effects of calmodulin antagonists on histamine release from human adenoi-dal mast cells. Arch, PharmacoL (1989) 339:R78.
   Google Scholar
• GIETZEN K, GLATZEL M, GOTTFIRED B: Effects of calmodulin antagonists on anaphylactoid reaction. Arch, Pharmacol, (1989) 339:R49.
   Google Scholar
• WYCZOLKOWSKA J, MASLINSKI C: Inhibition by nicoti-namide of an homologous PCA reaction and antigen-induced histamine release from rat peritoneal mast cells. Int. Arch, AllergyAppL Immunol. (1975) 49:285–292.
   Web of Science ®Google Scholar
• BEKIER E, WYCZOLKOWSKA J, SZYCH H et al.: The in-hibitory effects of nicotinamide on asthma-like symp-toms and eosinophilia in guinea pigs, anaphylactic mast cell degranulation in mice and histamine release from rat peritoneal mast cells by compound 48/80. Int, Arch, Allergy Appl, Immunol, (1974) 47:747–748.
   Google Scholar
• BEKIER E, MASLINSKI C: Antihistaminic action of nicoti-namide. Agent Actions (1974) 4:196.
   PubMedGoogle Scholar
• PENG B, LI Q ROBERGE F, WHITCUP SM, LUYO D, CHAN CC: Topical rapamycin inhibits allergic conjunctivitis in a murine model. Invest, OphthalmoL Vis, Sc!. (1994) 35 (Suppl.):1292.
   Google Scholar
• NICHOLSON CD: Inhibitors of cyclic nucleotide phos-phodiesterase isoenzymes. New Therapies for Allergic Disease Conference, IBC Tech, London, UK. (1993).
   Google Scholar
• TAYLOR WA, SHELDON D: Effect of lung tissue on the inhibitory actions of isoprenaline, theophylline, diso-dium cromoglycate and PGE1 on antigen-induced mast cell degranulation. Int. Arch, Allergy AppL ImmunoL (1977) 54:322–328.
   PubMedGoogle Scholar
• PAUWELS R: Future of anti-inflammatory therapy in asthma. Allergy (1995) 50 (Suppl. 22):27–31.
   Google Scholar
• Alizo Nobel Pharma Human ethicals R&D pipeline. NV Organon Company Communication (1996) October 10.
   Google Scholar
• ABELSON M, GEORGE M, DRAKE M, VONTRESS M, MILLER B: Evaluation of rimexolone ophthalmic suspension in the antigen challenge model of allergic conjunctivi-tis. Invest, Ophthalmol, Vis, Sc!. (1992) 33 (Suppl.):1112.
   Google Scholar
• MORTEMOUSQUE B, DOROT N, BARACH D, VERIN P: A new corticosteroid (rimexolone) with no ocular hy-pertensive effect in treatment of vernal keratocon-junctivitis (VKC). Invest, OphthalmoL Vis, Sc!. (1997) 38 (Suppl.):S132.
   Google Scholar
• KEATES EU, DRUZGALA PD, HOWES JF, REAVES TA: Lo-teprednol etabonate: a new steroid without ocular hy-pertensive effect. Invest, Ophthalmol, Vis, Sc!. (1991) 32 (Suppl.) :947.
   Google Scholar
• DRUZGALA PD, WU WM, WINWOOD D, HOWES JF, REAVES TA: Ocular absorption and distribution of lo-teprednol etabonate: a soft steroid. Invest, OphthalmoL Vis, Sc!. (1991) 32 (Suppl.):735.
   Google Scholar
• GEORGE M, ABELSON M, HOWES J: A randomized, double-masked, placebo-controlled paired compari-son of loteprednol etabonate 0.1%, 0.2% or 0.3% oph-thalmic suspension (LE) versus placebo in an antigen challenge model of acute allergic conjunctivitis. Invest, Ophthalmol. Vis, Sc!. (1997) 38(Suppl.):S427.
   Google Scholar
• ZBYSZYNSKI B, ABELSON M, HOWES J: A randomized, double-masked, placebo-controlled paired comparison of loteprednol etabonate 0.5% ophthal-mic suspension (LE) BID or QID versus placebo in an antigen challenge model of acute allergic conjunctivi-tis. Invest, Ophthalmol, Vis, Sci, (1997) 38(Suppl.):S426.
   Google Scholar
• HOWES J, STRAHLMAN E: Loteprednol Etabonate Study Group 2. A randomized, double-masked, placebo-controlled parallel group study of the effects of lo-teprednol etabonate 0.2% ophthalmic suspension (LE) in patients with seasonal allergic conjunctivitis. Invest. Ophthalmol,Vis, Sci, (1997) 38 (Suppl.):S427.
   Google Scholar
• STRAHLMAN E, HOWES J: Loteprednol Etabonate Study Group 2. A randomized, double-masked, placebo-controlled parallel group study of the effects of lo-teprednol etabonate 0.2% ophthalmic suspension (LE) in patients with seasonal allergic conjunctivitis. Invest, OphthalmoL Vis, Sci, (1997) 38 (Suppl.):S213.
   Google Scholar
• BARTLETT JD, HOWES JF, GHORMELY NR et al.: Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary con-junctivitis. Cum Eye Res, (1993) 12:313–321.
   PubMed Web of Science ®Google Scholar
• InSite Vision Annual Report (1994).
   Google Scholar
• HARPER DG, CHEN CE, FRIEDLANDER MH: Controlled comparison of two fluoromethalone formulations in the antigen challenge model of allergic conjunctivitis. CLAO .1 (1995) 21:256–260.
   PubMedGoogle Scholar
• Arris' asthma drug APC-366 shows promising results. Arris Pharmaceutical Corp. Press Release (30 April 1996).
   Google Scholar
• FLACH AJ: Topical nonsteroidal antiinflammatory drugs for ophthalmic use. Int. OphthalmoL Cl/n. (1996) 36:77–83.
   PubMed Web of Science ®Google Scholar
• BUCKLEY DC, CALD WELL DR, REAVES TA: Treatment of vernal conjunctivitis with suprofen, a topical non-steroidal anti-inflammatory agent. Invest, OphthalmoL Vis, Sci, (1986) 27:29–37.
   PubMedGoogle Scholar
• WOOD TS, STEWARD RH, BOWMAN RW: Suprofen treat-ment of contact lens-associated GPC. Ophthalmology (1988) 96:822–826.
   Google Scholar
• LAIBOVITZ RA, KOESTER J, SCHAICH L, REAVES TA: Safety and efficacy of diclofenac sodium 0.1% ophthal-mic solution in acute seasonal allergic conjunctivitis. J. Ocular Pharmacol, Then (1995) 11:361–368.
   Google Scholar
• MALDONADO GGH, MONTANO AJR, SUAREZ SR et al.: Comparison of the use of non steroid antiinflamma-tory (sodium flurbiprofen) and topical steroidal (prednisolone) on chronic allergic conjunctivitis. In-vest, OphthalmoL Vis, Sci. (1996) 37 (Suppl.):S592.
   Google Scholar
• SYRBOPOULOS S, GILBERT D, EASTY DL: Double-blind comparison of a steroid (prednisolone) and a non-steroid (tolmetin) in vernal keratoconjunctivitis. Cor-nea (1986) 5:35–39.
   Google Scholar
• BALLAS Z, BLUMENTHAL M, TINKELMAN D: Clinical evaluation of ketorolac tromethamine 0.5% ophthal-mic solution for treatment of seasonal allergic con-junctivitis. Surv. OphthalmoL (1993) 38 (Suppl.) :141–148.
   Google Scholar
• TINKELMAN D, RUPP G, KAUFMAN H et al.: Double-masked paired comparison clinical study of ketorolac tromethamine 0.5% solution compared with placebo eyedrops in the treatment of seasonal allergic con-junctivitis. Surv, OphthalmoL (1993) 38(Suppl ) 133–40
   Google Scholar
• GUZMAN A, HERNANDEZ A, CLIMENT A, MUNOZ S, GRAUE E: Non steroid antiinflammatory solutions as alternative on allergic conjunctivitis treatment. Invest, Ophthalmol, Vis, Sci, (1996) 3 7(Suppl.):S311.
   Google Scholar
• Ketorolac for seasonal allergic conjunctivitis [Edito-rial]. Med. Lett, Drugs Then (1993) 35:88–89.
   PubMedGoogle Scholar
• NATHAN H, NAVEH N, MEYER E: Levels of prostaglandin Ey and leukotriene Bg in tears of vernal conjunctivitis patients during a therapeutic trial with indomethacin. Doc, OphthalmoL (1994) 85:247–257.
   PubMed Web of Science ®Google Scholar
• ABELSON MB, BUTRUS SI, WESTON JA: Aspirin therapy in vernal conjunctivitis. Am, J. OphthalmoL (1983) 95:502–505.
   PubMed Web of Science ®Google Scholar
• SRINAVAS C: Adjuvant therapy of aspirin and cromo-glycate 2% eyedrops in vernal conjunctivitis. Korean J. OphthalmoL (1989) 3:42–46.
   PubMedGoogle Scholar
• CHAN C-C, BOYCE S, BRIDEAU C et al.: Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,334: a novel non-steroidal anti-inflammatory agent with an ulcerogenic sparing effects in rat and non-human pri-mate stomach. J. PharmacoL Exp. Then (1995) 274:1531–1537.
   PubMed Web of Science ®Google Scholar
• HOLGATE ST, BRADDING P, SAMPSON AP: Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. I Allergy Clin. Immune'. (1996) 98:1–13.
   PubMed Web of Science ®Google Scholar
• NATHAN RA: Anti-leukotriene agents: a new direction in asthma therapy. J. Asthma (1996) 33:353–366.
   PubMed Web of Science ®Google Scholar
• CHUNG KF: Leukotriene receptor antagonists and bio-synthesis inhibitors: potential breakthrough in asthma therapy. Eur. Respin J. (1995) 8:1203–1213.
   PubMed Web of Science ®Google Scholar
• SPECTOR SL: Leukotriene inhibitors and antagonists in asthma. Ann, Asthma ImmunoL (1995) 75:463–473.
   PubMed Web of Science ®Google Scholar
• LIU CS, RAMIREZ FLOREX S, WATSON PG: A randomised double blind trial comparing the treatment of epis- cleritiswithtopical2-(2-hydroxy-4-methylphenyl) aminothiazole hydrochloride 0.1% (CBS 113A) and placebo. Eye (1991) 5:678–685.
   Google Scholar
• WIRTH K, HEITSCH H, SCHOLKENS BA: Kinin receptor antagonists: unique probes in basic and clinical re-search. Can, J. PhysioL PharmacoL (1995) 73:797–804.
   PubMed Web of Science ®Google Scholar
• STEWART JM: Bradykinin antagonists: development and applications. Biopolymers (Peptide Science) (1995) 37:143–155.
   PubMed Web of Science ®Google Scholar
• AKBARY MA, BENDER N: Efficacy and safety of HOE 140 (bradykinin antagonist) in patients with mild-to-moderate seasonal allergic rhinitis. Proc, of KININ. Gua-ruja, Brazil (1993) 10:17-22. L151.
   Google Scholar
• AUSTIN CE, FOREMAN JC, SCADDING GK: Reduction by Hoe 140, the B2 kinin receptor antagonist, of antigen-induced nasal blockage. Br. J. Pharmacol, (1994) 1 11:969–971.
   Google Scholar
• PROUD D, BATHON JM, TOGIAS AG, NACLERIO RM: Inhi-bition of the response to nasal provocation with bra-dykinin by HOE-140: efficacy and duration of action. Can. J. PhysioL PharmacoL (1995) 73:820–826.
   PubMed Web of Science ®Google Scholar
• KOLTAI M, GUINOT P, HOSFORD D, BRAQUET PG: Platelet-activating factor antagonists: scientific back-ground and possible clinical applications. Adv. Phar-macoL (1994) 28:81–167.
   PubMedGoogle Scholar
• GUINOT P: Clinical experience with platelet-activating factor antagonists. Din. Rev. Allergy (1994) 12:397–417.
   PubMedGoogle Scholar
• BENFIELD TL, LUNDGREN JD: PAF receptor antagonists in the treatment of asthma. Exp. Opin, Invest. Drugs (1994) 3:733–742.
   Google Scholar
• Glaxo Wellcome scraps British Biotech's lexipafant for asthma. Bioworld International (1996) 1:5–6.
   Google Scholar
• Lexipafant dropped for asthma. SCRIP (1996) 2167:21.
   Google Scholar
• Chemex halts development of TCV-309. SCRIP (1994) 1927:22.
   Google Scholar
• ICOS plans trials with ICM-3. SCRIP (1997) 2211:22.
   Google Scholar
• GIRAL M, MERLOS M, BALSA D et al.: Evaluation of the histamine and PAF antagonist activity of the novel compound UR-12592. Int. Cong. AllergoLImmunoL(1994) Suppl 2:1011.
   Google Scholar
• BAZAN HE, TAO Y, HURST JS: Platelet-activating factor antagonists and ocular inflammation. J. Ocular Phar-macol, Then (1994) 10:319–327.
   PubMed Web of Science ®Google Scholar
• BAZAN HE, TAO Y: PAF antagonists as possible inhibi-tors of corneal epithelial defects and ulceration. J. Ocu-lar PharmacoL Then (1997) 13:277–285.
   PubMed Web of Science ®Google Scholar
• RUBIN RM, SAMPLES JR, ROSENBAUM JT: Prostaglandin-independent inhibition of ocular vascular permeabil-ity by a platelet-activating factor antagonist. Arch. Oph-thalmoL (1988) 106:1116–1120.
   PubMed Web of Science ®Google Scholar
• InSite Vision announces successful Phase I clinical trial of ISV-611. InSite Vision Inc. Press Release. (11 March 1997).
   Google Scholar
• Third Bath International Symposium on Medicinal Chemistry, Bath. /Ddb Meeting Report. (22–24 September 1996).
   Google Scholar
• Spectra Biomedical finds common genetic basis for al-lergies, heart disease and arthritis. Spectra Biomedical Press Release (19 April 1996).
   Google Scholar
• TUCK AW: T cell Sciences annual meeting. T-cell Sci-ences Press Release. (18 May 1995).
   Google Scholar
• ASWAD MI, TAUBER J, BAUM J: Plasmapheresis treat-ment in patients with severe atopic keratoconjunctivi-tis. Ophthalmology (1988) 95:444–447.
   PubMed Web of Science ®Google Scholar
• HENDERSON B, POOLE S: Modulation of cytokine func-tion: therapeutic applications. Adv. Pharmacol. (1994) 25:53–115.
   PubMedGoogle Scholar
• ROBINSON DS, HAMID Q, YING S et al.: Predominant Th2-like bronchoalveolar T lymphocyte population in atopic asthma. New Engl. J. Med. (1992) 326:298–304.
   PubMed Web of Science ®Google Scholar
• WECKMANN AL, ALCOCER-VARELA J: Cytokine inhibi-tors in autoimmune diseases. Semin, Arthritis Rheum. (1996) 26:539–557.
   PubMed Web of Science ®Google Scholar
• CARDI G, CIARDELLI TL, ERNSTOFF MS: Therapeutic ap-plications of cytokines for immunostimulation and immunosuppression: an update. Prog, Drug Res. (1996) 47:211–250.
   PubMedGoogle Scholar
• Hoffmann-La Roche and Protein Design Labs an-nounced that new phase III Zenepax clinical results show six month improvement in mortality and graft survival. Hoffmann-La Roche Inc. Press Release. (18 Febru-ary 1997).
   Google Scholar
• Protein Designs Labs granted US patent to Zenapax and other antibodies against the interleukin-2 recep-tor. Protein Design Labs, Inc. Press Release. (26 June1996).
   Google Scholar
• MULLARKEY MF, LEIFERMAN KM, PETERS MS et al.: Hu-man cutaneous allergic late-phase response is inhib-ited by soluble IL-1 receptor. J Immunol, (1994) 152:2033–2041.
   PubMed Web of Science ®Google Scholar
• SAVELKOUL HFJ, VAN OMMEN R: Role of IL-4 in persis-tent IgE formation. Eur, Respir, J. (1996) 9\(Suppl. 22)67–71.
   Google Scholar
• BACH JF: Cytokine-based immunomodulation of auto-immune diseases: an overview. Transplant Proc. (1996) 28:3023–3025.
   PubMed Web of Science ®Google Scholar
• TARTOUR E, LEE RS, FRIDMAN WH: Anti-cytokines: promising tools for diagnosis and immunotherapy. Biomed, Pharmacother, (1994) 48:417–424.
   PubMed Web of Science ®Google Scholar
• CRABTREE GR: The mechanisms of action of cyclo- sporin A and FK506.ImmunoL ImmunopathoL(1996) 80:S40–45.
   Google Scholar
• IWAMOTO H, YOSHIDA H, YOSHIDA O, FUKUSHIMA A, UENO H: Inhibitory effects of FK-506 on the induction of experimental allergic blepharoconjunctivitis in Lewis rats. Invest. Ophthalmol, Vis, Sci, (1997) 38 (Suppl.):1080.
   Google Scholar
• Taiho's suplatast tosilate launched in Japan. SCRIP (1995) 2029:18.
   Google Scholar
• CUSS FM: Therapy of allergic disease based on cytoki-nes. New Therapies for allergic diseases conference. (15–16 Feb 1993) IBC Tech., London, UK..
   Google Scholar
• LUGER TA: Cytokine treatment of mast-cell-mediated skin diseases. Exp. DermatoL (1995) 4:277–280.
   PubMedGoogle Scholar
• Guidebook to Cytokines and their Receptors. Nicola NA (Ed.), Oxford University Press, Oxford, UK (1994).
   Google Scholar
• KALDEN JR: Biologic agents in the therapy of inflamma-tory rheumatic disease, including therapeutic antibod-ies, cytokines and cytokine antagonists. Cum Op/n. Rheumatol, (1994) 6:281–286.
   PubMedGoogle Scholar
• MORELAND LW, BUCY RP, JACKSON B, JAMES T, KOOP-MAN WJ: Long-term (5 years) follow-up of rheumatoid arthritis patients treated with a depleting anti-CD4 monoclonal antibody cM-T412. Arthritis Rheum. (1996) 39 (Suppl.):S244.
   Google Scholar
• MORELAND LW, PRATT PW, MAYES MD et al.: Double-blind, placebo-controlled multicenter trial using chi-meric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum. (1995) 38:1581–1588.
   PubMed Web of Science ®Google Scholar
• KAINE J, SOLINGER A, YOCUM D et al.: Results of a multi-dose protocol 7002 using an immunomodulating non-depleting primatized anti-CD4 monoclonal anti-body in rheumatoid arthritis (RA). Arthritis Rheum. (1995) 38(Suppl.):185.
   Google Scholar
• VAN DEVENTER SJ, CAMOGLIO L: Monoclonal antibody therapy of inflammatory bowel disease. Alimentary Pharmacol, Then (1996) 10\(Suppl. 2)107–111.
   Google Scholar
• DELMONICO FL, COSIMI AB: Anti-CD4 monoclonal anti-body therapy. Clin, Transplant. (1996) 10:397–403.
   PubMed Web of Science ®Google Scholar
• IDEC Pharmaceuticals and SmithKline Beecham place hold on clinical testing of IDEC-CE9.1/SB-210396 for treatment of rheumatoid arthritis. IDEC Pharmaceuti-cals Corp. Press Release. (24 June 1997).
   Google Scholar
• HALE G, PHILLIPS JM: Clinical trials with CAMPATH-1 and other monoclonal antibodies. Biochem, Soc. Trans. (1995) 23:1057–1063.
   PubMed Web of Science ®Google Scholar
• Biocryst plans ophthalmic BCX-34. SCRIP (1996) 2126:23.
   Google Scholar
• ALLISON AC, KOWALSKI WJ, MULLER RD, EUGUI EM: Mechanism of action of mycophenolic acid. Ann. NY Acad. Sci, (1993) 696:63–87.
   PubMed Web of Science ®Google Scholar
• CORNEJO CJ, WINN RK, HARLAN JM: Anti-adhesion ther-apy. Adv. Pharmacol, (1997) 39:99–142.
   PubMedGoogle Scholar
• BOSCHELLI DH, KRAMER JB, KHATANA SS et al.: Inhibi-tion of E-selectin, ICAM-1- and VCAM-1-mediated cell adhesion by benzothiophene-, benzofuran-, indole-and naphthalene-2-carboxamides: identification of PD 144795 as an antiinflammatory agent. J. Med. Chem. (1995) 38:4597–614.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH AF, DAVIS LS, NICHOLS LA et al.: Treat-ment of refractory rheumatoid arthritis with a mono-clonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. (1994) 7:992–999.
   Google Scholar
• IMTIX' odulimomab in Phase III. SCRIP (1996) 2180:26.
   Google Scholar
• WHITCUP SM, CHAN CC, KOZHICH AT, MAGONE MT: In-hibition of allergic conjunctivitis by blocking ICAM-1 and LFA-1. Invest. Ophthalmol, Vis, Sci, (1997) 38(Suppl.):S727.
   Google Scholar
• TROCME SD, HALLBERG C: Heparin prevents eosino-phil granule major basic protein inhibition of corneal epithelial wound healing in the rat. Invest. Ophthalmol, Vis, Sci, (1993) 34 (Suppl.):1317.
   Google Scholar